MabThera/Rituxan

AbbVie and Roche plan Venclexta combo filings in leukaemia

MURANO trial shows the duo’s treatment extends PFS. AbbVie and Roche's long-anticipated combination trial of Venclexta/Venclyxto and Rituxan in chronic lymphocytic leukaemia, setting up regulatory filings for ... The phase III MURANO trial pithed the

Sandoz says Humira biosimilar clears clinical hurdle

review of the company's biosimilar version Roche's immunotherapy drug Rituxan (rituximab), another blockbuster with sales of $4bn in the first half of the year.

Roche faces prospect of second Rituxan biosimilar in US

The US Food and Drug Administration (FDA) has started its review of a second biosimilar rival to Roche's blockbuster immunotherapy drug Rituxan, with Novartis' Sandoz unit seeking to dent its ... Rituxan is used to treat blood cancers including

Kite files first CAR-T candidate in Europe

cytokine-release syndrome (CRS), which can be fatal if not managed but has also been seen with antibody therapies such as Roche's MabThera (rituximab).

Ocrevus off to a flying start as Roche raises 2017 forecasts

Roche's mainstay biologic cancer therapies also held up well in the face of biosimilar competition in some markets, with Herceptin (trastuzumab) and MabThera/Rituxan (rituximab) both gaining 3% to

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]